HNRNPA2B1 has demonstrated to interact with tau protein in regulating the progression of AD, and reduction of HNRNPA2B1 could reduce the pathological formation of tau protein (Jiang et al., 2021). This evidence concerns the gene MAPT and Alzheimer disease.